Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Cardiovascular, Case Report
Cardiovascular, Editorial
Cardiovascular, Images in Cardiology
Cardiovascular, Interventional Round
Cardiovascular, Original Article
Cardiovascular, Preface
Cardiovascular, Review Article
Cardiovascular, Student’s Corner
Case Report
Case Reports
Clinical Discussion
Clinical Rounds
CPC
Debate
Dedication
Editorial
Expert Comments
Expert's Opinion
Genetic Autopsy
Genetics Autopsy
Image in Cardiology
Images in Cardiology
Interventional Round
Interventional Rounds
Letter to the Editor
Media and news
Original Article
Practice in Medicine
Preface
Review Article
Scientific Paper
Short Communication
Student's Corner
WINCARS Activities
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Cardiovascular, Case Report
Cardiovascular, Editorial
Cardiovascular, Images in Cardiology
Cardiovascular, Interventional Round
Cardiovascular, Original Article
Cardiovascular, Preface
Cardiovascular, Review Article
Cardiovascular, Student’s Corner
Case Report
Case Reports
Clinical Discussion
Clinical Rounds
CPC
Debate
Dedication
Editorial
Expert Comments
Expert's Opinion
Genetic Autopsy
Genetics Autopsy
Image in Cardiology
Images in Cardiology
Interventional Round
Interventional Rounds
Letter to the Editor
Media and news
Original Article
Practice in Medicine
Preface
Review Article
Scientific Paper
Short Communication
Student's Corner
WINCARS Activities
View/Download PDF

Translate this page into:

Review Article
COVID-19: Women’s Health Issues
5 (
03
); 264-270
doi:
10.1055/s-0040-1716134

The Neurological Aspects of COVID-19: Do Women Respond Differently?

Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Department of Neurology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Address for correspondence Aastha Takkar, MD, DM Department of Neurology, Post Graduate Institute of Medical Education and Research Chandigarh, 160012 India draastha49@yahoo.com
Licence
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Private Ltd. and was migrated to Scientific Scholar after the change of Publisher; therefore Scientific Scholar has no control over the quality or content of this article.

Abstract

Abstract

Neurovirulence of Coronavirus-2 (SARS-CoV-2) was established soon after the Coronavirus disease-19 (COVID-19) pandemic broke. While the initial reports from Chinese cohorts suggested that around 8 to 36% patients of COVID-19 develop neurological complications, upcoming literature revealed the various neurological presentations this newly emergent virus could have. Data on neurological manifestations of COVID-19 is still accumulating. Despite an immense flooding of recent databases, gender-specific issues of this novel virus still remain elusive. Increased mortality has been noted in elderly male patients, and immediate risk of death is a major concern. As per the available literature, women are more likely to recover from the virus, but little is described about the medical and social repercussions. Gender-based analysis should help delineate specific problems in women in the rapidly changing scenario. This article discusses the relevant neurological aspects of COVID-19 with specific reference to women.

Keywords

COVID-19
neurological manifestations
SARS-CoV-2
stroke
women

Introduction

Neuroinvasiveness of Orthocoronavirinae subfamily, severe acute respiratory syndrome Coronavirus-1 (SARS-CoV-1) and Middle East respiratory Coronavirus (MERS-CoV), has been well-established. When the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2)/Coronavirus disease-19 (COVID-19) pandemic broke, neurological repercussions were expected round the corner.1

Initial reports from Chinese cohorts suggested that around 8 to 36% patients of COVID-19 develop neurological complications. With upcoming literature on varied presentations of this newly emergent virus, we are getting wiser about the myriad manifestations it can have.2 Despite an immense flooding of recent databases, gender-specific issues of this novel virus still remain elusive. Gendered effects of a pandemic are well-expected at all fronts–social, physical, financial and, of course, medical.

Search Strategy and Methodology

Medical databases were searched for relevant literature using the following key words: “Coronavirus,” “COVID-19,” “Neurological,” “Gender,” “Women,” “Encephalopathy,” and “CNS.” Original studies, case reports, review articles, letters to editor, and neurological images were selected for review. This manuscript presents a narrative review along with a neurologist’s perspective on COVID-19 in women.

Neurological Manifestations of COVID-19

What started as an unexplained pneumonitis in territories of Wuhan, rapidly spread beyond the geographical boundaries and was declared as a pandemic in March 2020. By the time the COVID-19 pandemic was inevitable, literature had already accumulated, suggesting the wide spectrum of manifestations COVID-19 can have. Extrapolation of studies on other viruses in the orthocronaviradae group like SARS-CoV-1 and MERS also suggested the neurotropic potential of the novel SARS-CoV-2.

Neurovirulence of COVID-19- the Etiopathogenesis

Neurological manifestations of COVID-19 are unique in exhibiting additional pathophysiological aspects. While the exact pathogenesis is still not established fully, the primary target of COVID-19 is believed to be the respiratory epithelium. Neurological complications are considered secondary and may arise due to direct invasion, immune-mediated damage or secondary complications like hypoxia or shock.

  1. Direct Neuroinvasion

    Neurotropism of SARS-CoV-2 has been well-established. It should be remembered that the brain becomes more susceptible to direct invasion when the blood–brain barrier is disrupted due to an uncontrolled systemic inflammatory response. The routes by which it enters the central nervous system (CNS) are as follows:3 4

    • Olfactory epithelium: Retrograde entry to CNS may occur through cribriform plate

    • Cellular infection and invasions: The infected macrophages act as a viral reservoir and spread to the brain. Both hematogenous as well as lymphatic routes have been described

    • Endothelial cells of the blood–brain barrier are known to express SARS-CoV receptors–the angiotensin-converting enzyme-2(ACE-2) and CD209L. ACE-2 is also expressed in glial cells, cerebral blood vessels, spinal cord, and skeletal muscles.5

    • Transsynaptic route: Transmission may also occur through the peripheral nerves

  2. Immune-mediated Injury–An aberrant immune-mediated response may be incited, giving rise to many parainfectious/postinfectious neurological complications.

    The virus effectively evades the host’s immune response, while the uncontrolled systemic inflammatory response/cytokine storm is a major cause of mortality in COVID-19.6

  3. Systemic Involvement: Severe respiratory distress causes systemic hypoxia. Hypercarbia and vasodilatation are indirect consequences, worsening the anerobic metabolism and causing neuronal cell death. SARS-Cov-2 can lead to multiorgan failure and systemic involvement, causing uremic encephalopathy or hypoxic encephalopathy. Disseminated intravascular coagulopathy (DIC)-mediated intracranial bleed or thrombosis is another major cause of mortality in these patients.

Neurological Manifestations of COVID-19- the Neurological Syndrome

The list of neurological manifestations in COVID-19 has been increasing over the past few months. Varying incidences of neurological manifestations have been observed in the available literature. In one of the initial retrospective series, Mao et al reported neurological complications in 36.4% of patients.2 Helms et al in their observational study reported a much higher incidence (84%) of neurological involvement.10 Many neurological complications (other than metabolic or hypoxic encephalopathy) tend to occur early in the disease course and in general, neurological manifestations have been associated with a severe respiratory infection. Practically, every part of both central and peripheral nervous system (CNS and PNS) can be involved in COVID-19. Fig. 1 shows an overview of potential neurological complications in a patient of COVID-19.

Fig. 1 An overview of neurological manifestations of COVID-19

Fig. 1 An overview of neurological manifestations of COVID-19

CNS Manifestations

CNS manifestations may arise due to focal or diffuse involvement of meninges, parenchymal structures, spinal cord and involvement of cerebral vasculature. CNS involvement is rather the most common neurological presentation. Symptomology may vary, depending upon the anatomical substrate involvement.

Headache and dizziness are the most commonly described symptoms of neurological involvement. Incidence of headache among various available reports ranges from 8 to 13.6%.2 11 Meningeal irritation, meningeal inflammation, and increased intracranial pressure have been postulated as possible mechanisms causing headache. Worsening of an underlying primary headache syndrome, new onset personnel protective equipment (PPE)-related headache, stress, and tension type headaches can be other causes of headache. A thorough clinical history and examination should be done in all patients for an early recognition of the ominous causes of headache.

Meningeal involvement causing meningitis and meningoencephalitis have also been reported in observational studies, case series and case reports.10 Seizure and altered sensorium are common presentations. SARS-CoV-2 RNA was detected in cerebrospinal fluid (CSF) of a few patients of COVID-19 mediated meningoencephalitis. Viral clearance in CSF may precede the neurological involvement and therefore the detection may be delayed.12 13

Acute necrotizing hemorrhagic encephalitis related to intracranial cytokine storm may occur and has been related to a worse prognosis.14 Dogan et al also considered autoimmune encephalitis in their six patients, based upon their clinical symptomatology and response to plasmapheresis.15 Another case of anti-NMDA-R antibody positivity was reported by Panareillo et al. These findings highlight the importance of activation of an indirect pathway involving the immune system in SARS-CoV-2 infection.16

Rhombencephalitis causing ataxia, leukoencephalopathy with diffuse corticospinal involvement, delirium, executive disturbances, behavioral disturbances, sleep disorders, dementia, and movement disorders are other syndromes associated with COVID-19.17

No conclusive laboratory (including CSF analysis) or neuro–radiological investigations have been described. In a recently published series by Franke et al, varied neurological symptoms like myoclonus, oculomotor disturbances, delirium, dystonia, stroke, seizures, etc., were noted in 11 severely ill COVID-19 patients. They also noted increased levels of neurofilament light chain in the CSF of these patients. All patients in their cohort had antineuronal autoantibodies in serum or CSF.18

In a multi-institutional French cohort, authors reported various radiological abnormalities, including medial temporal lobe hyperintensities, nonconfluent multifocal white matter hyperintense signal intensities, and extensive, isolated white matter hemorrhages in nonstroke patients of COVID-19.19

Vascular Involvement

Of particular interest is the cerebrovascular involvement with COVID-19. Incidence of strokes reported in European and Chinese hospital COVID-19 registries is up to 2.5 to 6%. Mao et al in his cohort noted strokes in 6 (2.8%) out of 214 hospitalized COVID-19 patients (5 ischemic and 1 hemorrhagic stroke). These were large vessel strokes and were seen in association with severe COVID-19 illness. Cortical venous thrombosis has also been reported in small series.20 In the series by Oxley et al, large vessel strokes were noted in four men and one woman. In their cohort, all reported strokes were in the middle cerebral artery territory. No typical symptoms of COVID-19 infection were present at the outset in 3 of the 5 patients. D dimer was raised in all but one.

The proinflammatory and prothrombotic mechanisms causing stroke in COVID-19 have aroused a great deal of interest. Endothelial dysfunction, DIC and thrombotic microangiopathy associated with thrombocytopenia, elevated D-dimer and prolonged prothrombin time have been hypothesized as precursors. With profoundly elevated D-dimer levels, COVID-19 has been considered as a highly prothrombotic state. Combined with factors like immobilization, hypoxia, inflammation and stress, accelerated thrombosis has been seen to occur in severely ill/ICU-bound patients. Role of antiphospholipid antibodies causing multifocal infarction has also been suggested by few. Prevalence of lupus anticoagulant in as high as 91% patients has been reported. Autopsy studies have suggested associated venous thrombosis in lower limbs, lungs and pulmonary circulation. Endothelitis in kidney and small intestine vessels has also been reported. Extrapolating these findings to cerebral vasculature may explain the etiopathogenesis of ischemic and hemorrhagic arterial and venous strokes.21 22 23

Brainstem and Spinal CORD Involvement

A handful of case reports of patients with necrotizing myelitis are available. It has been postulated that the severe and refractory gastrointestinal or respiratory involvement could be contributed by affected central pathways involving area postrema or chemoreceptor trigger zone.24 Mortality associated with respiratory failure has been postulated to be neurogenic, resulting from involvement of respiratory centers of the brain.

Peripheral Nervous System

COVID-19 may cause isolated cranial neuropathies; specifically, olfactory nerve involvement has received special focus. Concerns of spread of infection during endonasal procedures have been raised since the early days of suspected community transmission.25 Olfactory and taste dysfunction are considered as early symptoms of COVID-19 and studies have reported variable involvement (5–88%). Anosmia, hyposmia, parosmia and phantosmia may occur (in descending order). Apart from suspected immune, local inflammatory and direct cytopathic responses, altered neurotransmission affecting serotonin/dopamine pathways and altered central pathways of olfaction have been implicated. Other cranial neuropathies causing optic or ocular nerve involvement have been infrequently reported.

Acute inflammatory demyelinating or axonal radiculoneuropathy/Guillain–Barre syndrome and its variants (Miller–Fisher Syndrome) have been noted, probably due to an aberrant immune response.

A large proportion of patients have reported myalgia and fatigue (14.9–44%) in various case series and observational studies. Myopathy was diagnosed on the basis of raised CPK (> 200 U/L) in 10.7% of Chinese patients who presented with weakness and fatigue.2 Muscle involvement can be because of direct invasion or as a result of extensive inflammation.

Neurological Complications Due to Secondary/Systemic Involvement

Hypoxia, hypotension or multiorgan failure related encephalopathy needs due consideration as it is a major cause of mortality. Uremia and acute respiratory distress syndrome (ARDS) may themselves be associated with many metabolic alterations. Similarly, critical illness associated neuropathy and myopathy also deserve mention, keeping in mind prolonged ventilatory support, immobilization and nutrition deprivation in these patients.

Depression and COVID-19

COVID-19 has negatively affected society’s mental health to a large extent. Uncertain disease course and prognosis, persistent shortage of resources for diagnosis and personnel protective gears, and limited available treatment options have been disturbing both for the care providers as well as patients. Mass home confinement, excessive media exposure, limited access to public/social gatherings and resultant financial losses during the pandemic have negatively contributed toward mental health. In a cross-sectional study involving 81 participants, depression was noted in 23.6% patients and 45.1% patients reported anxiety. Similar findings were noted in other studies.26 Healthcare workers are in particular at higher risk. In a multinational, multicenter study of 906 healthcare workers, Chew et al noted an extremely high-incidence of stress, anxiety, headache and lethargy.27

COVID-19–the Impact on Underlying Neurological Illnesses

Patients with long-standing neurological illnesses like motor neuron disease, myasthenia gravis, Parkinson’s disease, dementia, inflammatory neuropathy, and myopathy may have reduced mobility, disturbed swallowing and compromised respiratory functions. COVID-19 infection may cause further worsening of the underlying compromised lung functions.

Immunosuppressive modalities have been widely used in contemporary neurology. Immune dysregulation is seen in neuroimmunological disorders like multiple sclerosis (MS), neuromyelitis-optica spectrum disorder, myasthenia gravis, autoimmune encephalitis, inflammatory neuropathies, and myopathies. In addition, these patients are often on chronic immunosuppressive therapies. This cohort is not just prone to get superadded infections, but once infected may also exhibit a poorer prognosis. Interestingly, some disease modifying therapies causing moderate immunosuppression, used in MS, may provide a beneficial effect in preventing complications related to exuberant immune response, considering potential antiviral properties trials of Interferon β are underway. Fingolimod is also been considered as treatment for ARDS related to COVID-19.32 An immune-mediated illness may respond erratically to physical and mental stress, worsening its own disease course and causing significant morbidity.

In a community-based case control study on COVID-19 patients, it was concluded that patients with an underlying Parkinson’s disease experience substantial worsening of their motor and nonmotor symptoms. Altered pharmacokinetics of the dopaminergic treatment or infection-related systemic inflammatory response were postulated as probable mechanisms.33

Stress-related worsening of neurological diseases, particularly Parkinson’s disease, dementia, MS and epilepsy, is a well-established fact and needs to be considered while attending to these patients.34

Treatment Protocols of Neurological Illness During COVID-19 Pandemic

The ongoing COVID-19 pandemic has posed major health challenges for all faculties. Reorganization of existing healthcare paradigms and treatment protocols are needed, keeping in mind the safety strategies for healthcare workers (HCWs). Considering the probable neurological emergencies, overwhelmed healthcare facilities, shortage of screening and protective equipment, consensus statements for many neurological illnesses have been proposed by different national and international neurological societies.

Cerebrovascular accidents are a major neurological emergency. The concept of “protected Code Stroke” has taken into account various issues like robust screening, time-sensitive care at primary facilities, telemedicine, designating separate CT machines, intravenous thrombolysis, mechanical thrombectomy guidelines, and telerehabilitation facilities.35

Similarly, consensus statement on immunological diseases like MS has focused upon possible risks worsening the immunological disease process, risk of acquiring secondary infections, risks posed due to various immunomodulatory drugs, and risk of relapse.36

Neurological Complications Associated with Treatment of COVID-19

Chloroquine and hydroxychloroquine have been hyped with respect to prophylaxis and treatment of mild-to-moderate disease. The potential spectrum of neuropsychiatric manifestations includes agitation, sleep disturbances, mania, hallucinations, paranoia, depression, catatonia, psychosis, and suicidal ideations. De-novo headaches may occur in nearly 2.8% of patients. Other minor side effects are dizziness, visual field defects, paresthesia, and insomnia. Toxicity and overdose may cause seizures, syncope, hypokalemia, and cardiovascular collapse.37

COVID-19- the Impact on Health Care: Social and Economic Aspects

Neurological Implications of the Personnel Protective Equipment (PPE)

In a cross-sectional study involving 158 frontline HCWs, it was noted that PPE was associated with de-novo headache and also exacerbates preexisting headache disorders.38 Psychopathological implications of facemask was studied in another nationwide online survey which suggested that use of facemask could provide a sense of false security due to an increased level of self-perceived protection notion. This may adversely undermine other infection control measures39

Neurologist’s Perspective of Lockdown in COVID-19 Crisis

A general view of the lockdown-related issues can be extrapolated from a report published by the neurological alliance of Ireland which discussed the neurological impacts of restrictions imposed during the COVID-19 pandemic. Due to restrictions of physical visit to treating clinicians, limited access for healthcare providers, and withdrawal of home care by providers, 26% patients had difficulty in accessing neurological care and had reported subjective worsening.

Conclusions: The Future Perspective

Data on neurological manifestations in COVID-19 is still accumulating. The course of the disease is unfolding with every passing day, but there is evidence of increased mortality among elderly male patients. Gender specific response to illness looks to be a major factor in determining the differences in morbidity and mortality. For elderly men in general, the immediate risk of death from the disease is the greatest concern. For women, who are more likely to recover from the virus, other repercussions of COVID-19 may unfold subsequently and last for years to come. A consistent analysis of gender-specific data will ensure that specific needs of women, girls and marginalized groups are rendered visible. Woman-specific considerations should be given, while keeping in mind diagnostic, therapeutic and prophylactic measures.

Conflicts of interest

None declared.

Financial Disclosures/Funding Source None.

References

  1. , , , , , . Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014;194:145-158.
    [Google Scholar]
  2. , , , et al . Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(06):1-9.
    [Google Scholar]
  3. , , , . COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neurovirol. 2020;26(03):324-329.
    [Google Scholar]
  4. , , , et al . Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 2020;173:104646.
    [Google Scholar]
  5. , , . COVID-19 pandemic: A neurological perspective. Cureus. 2020;12(04):e7889.
    [Google Scholar]
  6. , , , , , . Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(02):102-108.
    [Google Scholar]
  7. , , , et al . Gender differences in patients With COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.
    [Google Scholar]
  8. , , , et al . Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
    [Google Scholar]
  9. , , , et al . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395 (10223):507-513.
    [Google Scholar]
  10. , , , et al . Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270.
    [Google Scholar]
  11. , , , et al , . Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
    [Google Scholar]
  12. , , , et al . A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55-58.
    [Google Scholar]
  13. , , , et al . Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid. Int J Infect Dis. 2020;96:567-569.
    [Google Scholar]
  14. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020 (e-pub ahead of print). doi: https://doi.org/10.1148/radiol.2020201187
  15. , , , et al . Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun. 2020;87:155-158.
    [Google Scholar]
  16. Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient_ A case report. Available at: https://reader.elsevier.com/reader/sd/pii/S0889159120308734?token=BB64C442B7FD351C5A45BAD49965C59F8970FBBD480497CE051D8E2480BFF97D2620B429D7BC2470756A50606D715A5C. Accessed July 31, 2020
  17. Bernard-Valnet R, Pizzarotti B, Anichini A, et al. Two patients with acute meningoencephalitis concomitant with SARSCoV-2 infection. Eur J Neurol 2020 (e-pub ahead of print). Doi: https://doi.org/10.1101/2020.04.17.20060251
  18. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Available at: https://www.medrxiv.org/content/10.1101/2020.07.01.20143214v1. Accessed July 31, 2020
  19. , , , et al . Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. 2020202222.
    [Google Scholar]
  20. , , . Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832.
    [Google Scholar]
  21. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Available at: https://www.acpjournals.org/doi/full/10.7326/M20-2003. Accessed July 31, 2020
  22. Acute ischemic stroke and COVID-19. Available at: https://www.ccjm.org/content/early/2020/06/01/ccjm.87a.ccc042. Accessed July 31, 2020
  23. , , , et al . Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.
    [Google Scholar]
  24. , , , et al . Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings. Radiol Case Rep. 2020;15(09):1591-1595.
    [Google Scholar]
  25. , , , et al . Letter: precautions for endoscopic transnasal skull base surgery during the COVID-19 pandemic. Neurosurgery. 2020;87(01):E66-E67.
    [Google Scholar]
  26. , , . Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66(05):504-511.
    [Google Scholar]
  27. , , , et al . A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav Immun. 2020;88:559-565.
    [Google Scholar]
  28. , , , , , , . Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. Int J Mol Sci. 2020;21(08):E2948.
    [Google Scholar]
  29. , , , et al . Sex hormones promote opposite effects on ACE and ACE2 activity, hypertrophy and cardiac contractility in spontaneously hypertensive rats. PLoS One. 2015;10(05):e0127515.
    [Google Scholar]
  30. Sex hormones and novel Corona virus infectious disease (COVID-19). Available at: https://reader.elsevier.com/reader/sd/pii/S0025619620305188?token=CF6B93EE45666910ADEDDFA5E815225999B1116EFD86CE6C9D0324E72A00C500E073037031E00254B8182D66E7B60A1C. Accessed July 31, 2020
  31. , , , , , . Do androgens modulate the pathophysiological pathways of inflammation? Appraising the contemporary evidence. J Clin Med. 2018;7(12):E549.
    [Google Scholar]
  32. , , , , , . Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949-952.
    [Google Scholar]
  33. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson’s disease clinical features: a community-based case-control study. Mov Disord 2020. (e-pub ahead of print). doi: https://doi.org/10.1002/mds.28170
  34. Psychiatric manifestations of neurologic disease: where are we headed? Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687521/. Accessed July 31, 2020
  35. , , , et al . Consensus statement - suggested recommendations for acute stroke management during the COVID-19 pandemic: Expert group on behalf of the Indian stroke association. Ann Indian Acad Neurol. 2020;23(07):15-23.
    [Google Scholar]
  36. , , , et al . Consensus statement on immune modulation in multiple sclerosis and related disorders during the COVID-19 pandemic: Expert Group on Behalf of the Indian Academy of Neurology. Ann Indian Acad Neurol. 2020;23:S5-S14.
    [Google Scholar]
  37. , . Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17):E450-E453.
    [Google Scholar]
  38. , , , et al . Headaches associated with personal protective equipment – A cross - sectional study among frontline healthcare workers during COVID-19. Headache J Head Face Pain.. 2020;60(05):864864.
    [Google Scholar]
  39. , , , et al . Psychopathological responses and face mask restrictions during the COVID-19 outbreak: results from a nationwide survey. Brain Behav Immun. 2020;87:161-162.
    [Google Scholar]
Show Sections